Meta-analyses, mainly derived from studies on patients with type 2 diabetes, found that liraglutide or exenatide treatment increased adiponectin levels [32] and reduced leptin levels [33], indicating that GLP-1R agonism has concordant effects on the size and secretome of adipose tissue. Here, GLP1R is linked to type 2 diabetes mellitus.